Form 8-K - Current report:
SEC Accession No. 0001104659-21-102172
Filing Date
2021-08-09
Accepted
2021-08-09 16:33:28
Documents
12
Period of Report
2021-08-09
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2124117d1_8k.htm   iXBRL 8-K 26711
  Complete submission text file 0001104659-21-102172.txt   201789

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vyne-20210809.xsd EX-101.SCH 3051
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20210809_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20210809_pre.xml EX-101.PRE 22376
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2124117d1_8k_htm.xml XML 3706
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 211156993
SIC: 2834 Pharmaceutical Preparations